The benefits of new innovations in glioblastoma therapies should not be curtailed as a result of delays in commencement of radiation therapy, caused by clinical circumstances as well as diagnostic procedures. This study evaluates whether delays in chemo-radiotherapy after surgery, while determining O6-methylguanineDNA-methyltransferase (MGMT) promoter status, affect the survival rates of patients with glioblastoma (GBM). |